Podocyte-Specific Deletion of MCP-1 Fails to Protect against Angiotensin II- or Adriamycin-Induced Glomerular Disease
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25094987 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Corry D Bondi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pittsburgh, Pittsburgh, PA 152671, USA. Hauptthemen laut MEDLINE: Chemokine CCL2, Podocytes, Doxorubicin, Angiotensin II. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, BLRD VA, NCI NIH HHS.
Abstract (Originalsprache)
Investigating the role of podocytes in proteinuric disease is imperative to address the increasing global burden of chronic kidney disease (CKD). Studies strongly implicate increased levels of monocyte chemoattractant protein-1 (MCP-1/CCL2) in proteinuric CKD. Since podocytes express the receptor for MCP-1 (i.e., CCR2), we hypothesized that podocyte-specific MCP-1 production in response to stimuli could activate its receptor in an autocrine manner, leading to further podocyte injury. To test this hypothesis, we generated podocyte-specific MCP-1 knockout mice (Podo-Mcp-1fl/fl) and exposed them to proteinuric injury induced by either angiotensin II (Ang II; 1.5 mg/kg/d, osmotic minipump) or Adriamycin (Adr; 18 mg/kg, intravenous bolus). At baseline, there were no between-group differences in body weight, histology, albuminuria, and podocyte markers. After 28 days, there were no between-group differences in survival, change in body weight, albuminuria, kidney function, glomerular injury, and tubulointerstitial fibrosis. The lack of protection in the knockout mice suggests that podocyte-specific MCP-1 production is not a major contributor to either Ang II- or Adr-induced glomerular disease, implicating that another cell type is the source of pathogenic MCP-1 production in CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA 152671, USA.
ORCID-Profile: Roderick J Tan
Förderung
- NIDDK NIH HHS
- BLRD VA
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
- American Heart Association
- Department of Veterans Affairs Merit Award
- National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Bondi, C. D., Hartman, H. L., Rush, B. M., & Tan, R. J. (2024). Podocyte-Specific Deletion of MCP-1 Fails to Protect against Angiotensin II- or Adriamycin-Induced Glomerular Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25094987
Vancouver
Bondi CD, Hartman HL, Rush BM, Tan RJ. Podocyte-Specific Deletion of MCP-1 Fails to Protect against Angiotensin II- or Adriamycin-Induced Glomerular Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25094987
BibTeX
@article{Bondi2024,
author = {Bondi, Corry D and Hartman, Hannah L and Rush, Brittney M and Tan, Roderick J},
title = {Podocyte-Specific Deletion of MCP-1 Fails to Protect against Angiotensin II- or Adriamycin-Induced Glomerular Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25094987}
}
EUVIMED